Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene’s product pipeline.
While Celgene’s top-selling blood cancer drug Revlimid (lenalidomide) was a key draw for Bristol-Myers, the pharma also made a case to skeptical investors that Celgene’s experimental drugs could give it a foundation for the future.
Among the five drugs highlighted by Bristol-Myers, Wall Street sales estimates for Inrebic are the lowest, ranging between $300 million to $500 million by 2028, according to an activist investor which opposed the Celgene deal.
Much more important are the multiple sclerosis drug ozanimod and the CAR-T cancer therapies bb2121 and lisocabtagene maraleucel.
All told, Bristol-Myers expects the five drugs plus one of its own to eventually generate more than $15 billion in annual revenue.
